ReviewJournal of diabetes investigation2016
Genetics of cardiovascular and renal complications in diabetes.
Review in Journal of diabetes investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy of traditional Chinese medication Tangminling pill in Chinese patients with type 2 diabetes.Bioscience reports · 2019Pooled it
- A Prospective Multicenter Assessment of the Accuracy and Safety of the Yuwell CT3 Real-Time Continuous Glucose Monitoring System in Patients With Diabetes Over 14 Days.Journal of diabetes · 2026Article
- Multi-trait GWAS reveals divergent local and polygenic architecture of cardiovascular traits across African and European ancestries in the UK Biobank.Communications biology · 2026Article
- Genetics of diabetes and its complications: a comprehensive review.Diabetology & metabolic syndrome · 2025Review
- The key mediator of diabetic kidney disease: Potassium channel dysfunction.Genes & diseases · 2024Review
- Lessons and Applications of Omics Research in Diabetes Epidemiology.Current diabetes reports · 2024Review
- Nephroprotective Effect ofCurrent pharmaceutical design · 2024Article
- Transcriptional profiles associated with coronary artery disease in type 2 diabetes mellitus.Frontiers in endocrinology · 2024Article
- Polygenic risk scores for cardiometabolic traits demonstrate importance of ancestry for predictive precision medicine.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2024Article
- Nephroprotective effect of remote ischemic conditioning on type 2 diabetic rats.Iranian journal of basic medical sciences · 2024Article
- DNA methylation and 28-year cardiovascular disease risk in type 1 diabetes: the Epidemiology of Diabetes Complications (EDC) cohort study.Clinical epigenetics · 2023Article
- Dysfunction of circulating CD3International journal of medical sciences · 2023Article
- Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis.International immunopharmacology · 2021Review
- Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases.Frontiers in pharmacology · 2021Review
- The Liability Threshold Model for Predicting the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Multi-Cohort Study of Korean Adults.Metabolites · 2020Article
- Long Non-Coding RNA (LncRNA) CASC15 Is Upregulated in Diabetes-Induced Chronic Renal Failure and Regulates Podocyte Apoptosis.Medical science monitor : international medical journal of experimental and clinical research · 2020Observational
- Cellular Senescence as the Pathogenic Hub of Diabetes-Related Wound Chronicity.Frontiers in endocrinology · 2020Review
- Sulforaphane: Its "Coming of Age" as a Clinically Relevant Nutraceutical in the Prevention and Treatment of Chronic Disease.Oxidative medicine and cellular longevity · 2019Review
- Precision medicine in diabetes prevention, classification and management.Journal of diabetes investigation · 2018Review
- Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease.Seminars in nephrology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of debilitating complications represents a major healthcare burden associated with the treatment of diabetes. Despite advances in new therapies for controlling hyperglycemia, the burden associated with diabetic complications remains high, especially in relation to cardiovascular and renal complications. Furthermore, an increasing proportion of patients develop type 2 diabetes at a younger age, putting them at higher risk of developing complications as a result of the increased exposure to hyperglycemia. Diabetes has become the main contributing cause to end-stage renal disease in most countries. Although there has been important breakthroughs in our understanding of the genetics of type 1 and type 2 diabetes, bringing important insights towards the pathogenesis of diabetes, there has been comparatively less progress in our understanding of the genetic basis of diabetic complications. Genome-wide association studies are beginning to expand our understanding of the genetic architecture relating to diabetic complications. Improved understanding of the genetic basis of diabetic cardiorenal complications might provide an opportunity for improved risk prediction, as well as the development of new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.